Reshaping the HIV treatment and prevention landscape

Industry leading portfolio High efficacy and protection Extensive and highly diversified portfolio Percentage of Vx Revenues Pneumococcal Hep A, B 8% 8% Rotavirus Other 11% 6% 28% 10% Influenza 13% Meningitis Vaccines revenues 2020 *DTP family vaccines (Diptheria, Tetanus, Pertussis, Hib, Polio and Hepatitis B) Shingles 16% DTP* 90% of portfolio offers >90% protection Shingles Efficacy rate | DTP* Meningitis Rotavirus Hep A, B Pneumococcal Influenza 50% 90% gsk 58

View entire presentation